晚期早产产前皮质类固醇减少新生儿呼吸系统并发症:一项随机对照试验
在印度南部单中心、三盲、安慰剂对照试验中,847名34至36 6/7周有早产风险的孕妇随机接受倍他米松或安慰剂。主要结局新生儿呼吸窘迫治疗率倍他米松组4.9% vs 安慰剂组4.8%,无统计学显著差异(RR 1.03,95%CI 0.57-1.84)。因无效提前终止。
要点
- 晚期早产(34至36 6/7周)使用倍他米松未降低新生儿呼吸窘迫治疗需求。
- 主要结局发生率倍他米松组4.9% vs 安慰剂组4.8%,RR 1.03(95%CI 0.57-1.84)。
- 新生儿和母体次要结局均无统计学显著差异。
核心结论
- 晚期早产期间对有早产风险者给予倍他米松未减少新生儿呼吸窘迫的治疗需求。
研究设计与样本
- 单中心、三盲、随机、安慰剂对照试验,在印度南部招募34至36 6/7周有早产风险的孕妇。
- 采用计算机生成区组随机化,参与者随机接受一疗程肌内注射倍他米松或安慰剂。
- 计划样本量1200例,把握度80%检测呼吸窘迫率降低30%;计划中期分析后因无效停止入组。
- 2020年3月至2022年8月招募847名参与者,倍他米松组423名,安慰剂组424名;22人失访。
- 所有分析基于意向治疗。
主要发现
- 主要结局(生后72小时内因呼吸窘迫接受氧疗、持续气道正压或机械通气至少2小时)倍他米松组4.9% vs 安慰剂组4.8%,相对风险1.03(95%CI 0.57-1.84),需治疗人数786,无统计学显著差异。
- 新生儿次要结局(新生儿暂时性呼吸增快、呼吸窘迫综合征、坏死性小肠结肠炎、脓毒症、高胆红素血症、低血糖、死产、早期新生儿死亡)和母体次要结局(绒毛膜羊膜炎、产后出血、产褥热、住院时间)均无统计学显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the efficacy of antenatal corticosteroids in reducing neonatal respiratory complications when administered to those at risk of preterm delivery between 34 and 36 6/7 weeks of gestation. METHODS: This was a single-center, triple-blind, randomized, placebo-controlled trial in southern India enrolling pregnant participants at risk of preterm delivery between 34 and 36 6/7 weeks of gestation. Computer-generated block randomization was used with participants randomized to either one course of intramuscular betamethasone or placebo. The primary outcome was a composite of treatment for respiratory distress in the neonate, defined as need for oxygen or continuous positive airway pressure or mechanical ventilation for at least 2 hours in the first 72 hours of life. Neonatal secondary outcomes were transient tachypnea of the newborn, respiratory distress syndrome, necrotizing enterocolitis, sepsis, hyperbilirubinemia, hypoglycemia, stillbirth, and early neonatal death; maternal secondary outcomes were chorioamnionitis, postpartum hemorrhage, puerperal fever, and length of hospitalization. All analyses were based on intention to treat. A sample size of 1,200 was planned with 80% power to detect a 30% reduction in rates of respiratory distress. After a planned interim analysis, enrollment was stopped for futility. RESULTS: From March 2020 to August 2022, 847 participants were recruited, with 423 participants randomized to betamethasone and 424 participants randomized to placebo. There were 22 individuals lost to follow-up. There was no statistically significant difference in the primary outcome (betamethasone 4.9% vs placebo 4.8%, relative risk 1.03, 95% CI, 0.57-1.84, number needed to treat 786). There were no statistically significant differences in secondary neonatal or maternal outcomes. CONCLUSION: Betamethasone administered in the late-preterm period to those at risk for preterm delivery did not reduce the need for treatment of neonatal respiratory distress. CLINICAL TRIAL REGISTRATION: Clinical Trials Registry of India, CTRI/2019/09/021321.
引用
- Yenuberi H, Ross B, Sasmita Tirkey R, et al. Late-Preterm Antenatal Steroids for Reduction of Neonatal Respiratory Complications: A Randomized Controlled Trial. Obstet Gynecol. 2024. PMID: 38330411. doi:10.1097/AOG.0000000000005520
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。